Charles Schwab Investment Management Inc. Sells 14,151 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Charles Schwab Investment Management Inc. cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 0.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,773,397 shares of the biopharmaceutical company's stock after selling 14,151 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 1.39% of Halozyme Therapeutics worth $101,509,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of HALO. GAMMA Investing LLC raised its stake in Halozyme Therapeutics by 96.6% in the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 254 shares during the period. International Assets Investment Management LLC acquired a new stake in Halozyme Therapeutics during the 2nd quarter valued at $33,000. Skandinaviska Enskilda Banken AB publ bought a new position in Halozyme Therapeutics during the second quarter worth $49,000. Toth Financial Advisory Corp bought a new position in Halozyme Therapeutics during the third quarter worth $57,000. Finally, FSC Wealth Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the third quarter valued at $65,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

HALO stock opened at $47.79 on Wednesday. Halozyme Therapeutics, Inc. has a 52 week low of $33.15 and a 52 week high of $65.53. The business has a 50-day simple moving average of $54.28 and a 200 day simple moving average of $53.68. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The company has a market cap of $6.08 billion, a PE ratio of 15.82, a price-to-earnings-growth ratio of 0.45 and a beta of 1.29.

Insider Activity

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the business's stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $52.58, for a total transaction of $525,800.00. Following the completion of the transaction, the chief executive officer now directly owns 676,744 shares in the company, valued at $35,583,199.52. The trade was a 1.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last ninety days, insiders sold 60,000 shares of company stock worth $3,425,000. 2.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on HALO. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and raised their target price for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. Benchmark restated a "buy" rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, August 8th. Morgan Stanley increased their target price on Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 7th. HC Wainwright restated a "buy" rating and issued a $68.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, November 20th. Finally, Cowen reiterated a "buy" rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, Halozyme Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $61.11.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.